Recreational O
use O
of O
GHB O
is O
associated O
with O
alterations O
of O
resting O
state O
functional O
connectivity O
of O
the O
central O
executive O
and O
default O
mode O
networks O
Abstract O
Gamma‐hydroxybutyrate O
acid O
( O
GHB O
) O
is O
a O
recreational O
drug O
with O
a O
high O
addictive O
potential O
. O

Severe O
side O
effects O
such O
as O
GHB‐induced O
coma O
are O
common O
and O
linked O
to O
increased O
emergency O
room O
attendances O
. O

Task‐based O
functional‐imaging O
studies O
have O
revealed O
an O
association O
between O
the O
regular O
use O
of O
GHB O
and O
multiple O
GHB‐induced O
comas O
, O
and O
altered O
neurocognitive O
function O
. O

However O
the O
effects O
of O
multiple O
GHB‐induced O
comas O
and O
regular O
GHB‐use O
on O
intrinsic O
brain O
connectivity O
during O
rest O
remain O
unknown O
. O

The O
study O
population O
consisted O
of O
23 O
GHB‐users O
with O
≥4 O
GHB‐induced O
comas O
( O
GHB‐Coma O
) O
, O
22 O
GHB‐users O
who O
never O
experienced O
a O
GHB‐induced O
coma O
( O
GHB‐NoComa O
) O
and O
24 O
polydrug O
users O
who O
never O
used O
GHB O
( O
No‐GHB O
) O
. O

Resting‐state O
scans O
were O
collected O
to O
assess O
resting‐state O
functional‐connectivity O
within O
and O
between O
the O
default O
mode O
network O
( O
DMN O
) O
, O
the O
bilateral O
central O
executive O
network O
( O
CEN O
) O
and O
the O
salience O
network O
( O
SN O
) O
. O

The O
GHB‐NoComa O
group O
showed O
decreased O
rsFC O
of O
the O
right O
CEN O
with O
a O
region O
in O
the O
anterior O
cingulate O
cortex O
( O
p O
FWE O
= O
0.048 O
) O
and O
decreased O
rsFC O
between O
the O
right O
CEN O
and O
the O
DMN O
( O
p O
FWE O
= O
0.048 O
) O
when O
compared O
with O
the O
No‐GHB O
group O
. O

These O
results O
suggest O
that O
regular O
GHB‐use O
is O
associated O
with O
decreased O
rsFC O
within O
the O
right O
CEN O
and O
between O
the O
right O
CEN O
and O
the O
DMN O
. O

The O
presence O
of O
multiple O
GHB‐induced O
comas O
is O
not O
associated O
with O
( O
additional O
) O
alterations O
in O
rsFC O
. O

MATERIALS O
AND O
METHODS O
Participants O
For O
this O
cross‐sectional O
study O
, O
77 O
participants O
were O
recruited O
through O
addiction O
centers O
in O
the O
Netherlands O
, O
flyers O
, O
internet O
advertisements O
, O
and O
snowball O
sampling O
. O

Three O
different O
groups O
of O
participants O
matched O
on O
age O
and O
education O
level O
were O
included O
: O
23 O
GHB‐users O
with O
≥4 O
GHB‐induced O
comas O
( O
GHB‐Coma O
) O
; O
22 O
GHB‐users O
without O
GHB‐induced O
comas O
( O
GHB‐NoComa O
) O
; O
and O
24 O
polydrug O
users O
who O
never O
used O
GHB O
( O
No‐GHB O
) O
. O

Inclusion O
criteria O
for O
all O
participants O
were O
: O
age O
between O
18 O
and O
40 O
years O
; O
native O
Dutch O
speaker O
; O
male O
gender O
( O
since O
the O
majority O
of O
GHB‐users O
are O
males O
; O
Miró O
et O
al. O
, O
2017 O
) O
. O

An O
additional O
inclusion O
criterion O
for O
GHB‐users O
was O
the O
use O
of O
GHB O
≥25 O
times O
in O
the O
last O
2 O
years O
preceding O
this O
assessment O
. O

An O
additional O
inclusion O
criterion O
for O
the O
GHB‐Coma O
group O
was O
a O
minimum O
of O
4 O
GHB‐induced O
comas O
in O
order O
to O
increase O
the O
contrast O
with O
the O
GHB‐NoComa O
group O
. O

Polydrug O
use O
( O
or O
co‐use O
) O
of O
other O
recreational O
drugs O
was O
defined O
as O
the O
use O
of O
alcohol O
, O
nicotine O
, O
cannabis O
, O
cocaine O
, O
any O
other O
stimulants O
( O
amphetamines O
, O
khat O
, O
methylphenidate O
) O
, O
ecstasy O
, O
ketamine O
, O
and/or O
sedatives O
( O
benzodiazepines O
) O
. O

The O
exclusion O
criteria O
for O
the O
study O
were O
: O
a O
history O
of O
epilepsy O
, O
general O
anesthesia O
in O
the O
2 O
years O
before O
the O
study O
; O
a O
contra‐indication O
for O
fMRI O
scanning O
( O
e.g. O
, O
metal O
objects O
in O
the O
body O
or O
head O
injury O
) O
; O
any O
coma O
unrelated O
to O
GHB‐use O
; O
and O
currently O
under O
treatment O
for O
narcolepsy O
with O
cataplexy O
( O
since O
treatment O
may O
involve O
the O
use O
of O
medication O
based O
on O
GHB O
) O
. O

After O
explanation O
of O
the O
study O
procedure O
, O
written O
informed O
consent O
was O
obtained O
from O
all O
participants O
prior O
to O
initiation O
of O
the O
study O
. O

This O
study O
was O
in O
accordance O
with O
the O
Helsinki O
Declaration O
principles O
( O
7th O
revision O
, O
2013 O
) O
, O
the O
Medical O
Research O
Involving O
Human O
Subjects O
( O
WMO O
, O
1998 O
) O
, O
and O
approved O
by O
the O
Medical O
Ethics O
Review O
Committee O
of O
the O
Academic O
Medical O
Centre O
( O
World O
Medical O
Association O
, O
2013 O
) O
. O

Procedure O
The O
data O
presented O
here O
were O
part O
of O
a O
larger O
study O
assessing O
the O
neurocognitive O
and O
neural O
effects O
of O
regular O
GHB‐use O
and O
GHB‐induced O
comas O
in O
humans O
. O

The O
study O
consisted O
of O
an O
initial O
urine O
test O
, O
followed O
by O
completing O
questionnaires O
related O
to O
GHB O
and O
other O
drug O
use O
, O
depression O
, O
anxiety O
, O
stress O
, O
and O
impulsivity O
levels O
. O

During O
the O
subsequent O
neuroimaging O
session O
, O
structural O
, O
and O
functional O
scans O
were O
collected O
in O
the O
following O
order O
: O
structural O
MRI O
; O
resting‐state O
fMRI O
; O
long‐term O
memory O
task O
; O
diffusion O
weighted O
imaging O
, O
working‐memory O
task O
; O
emotion O
processing O
. O

Finally O
outside O
the O
scanner O
, O
participants O
performed O
digitized O
neuropsychological O
tests O
, O
including O
verbal O
memory O
, O
spatial O
memory O
, O
intra‐extra O
dimensional O
set O
shifting O
, O
and O
probabilistic O
reversal O
learning O
. O

In O
this O
report O
we O
will O
present O
data O
focused O
on O
the O
rsFC O
analysis O
of O
this O
sample O
only O
. O

Other O
data O
from O
this O
study O
have O
been O
presented O
elsewhere O
( O
Raposo O
Pereira O
et O
al. O
, O
2018a O
, O
2018b O
) O
. O

Questionnaire O
and O
cognitive O
test O
Premorbid O
intellectual O
functioning O
was O
assessed O
with O
the O
Dutch O
version O
of O
the O
Adult O
reading O
test O
, O
as O
proxy O
for O
IQ O
( O
Schmand O
, O
Bakker O
, O
Saan O
, O
& O
Louman O
, O
1991 O
) O
. O

The O
MATE O
2:1 O
substance O
use O
section O
was O
used O
to O
assess O
the O
use O
of O
different O
recreational O
drugs O
( O
Schippers O
, O
Broekman O
, O
& O
Buchholz O
, O
2011 O
) O
. O

Statistical O
analysis O
Demographic O
and O
clinical O
data O
were O
analyzed O
with O
the O
SPSS24 O
software O
( O
IBM O
Software O
Analytics O
, O
New O
York O
, O
NY O
) O
. O

Normally O
distributed O
data O
were O
evaluated O
through O
analysis O
of O
variance O
( O
ANOVA O
) O
. O

If O
not O
normally O
distributed O
, O
data O
was O
transformed O
in O
order O
to O
obtain O
a O
normal O
distribution O
or O
evaluated O
with O
nonparametric O
tests O
) O
. O

Group O
differences O
in O
GHB O
daily O
dose O
( O
mL/day O
) O
, O
years O
since O
first O
use O
, O
prevalence O
of O
days O
using O
GHB O
on O
the O
previous O
month O
, O
months O
of O
daily O
use O
, O
and O
total O
exposure O
as O
defined O
by O
years O
of O
use O
× O
daily O
dose O
, O
were O
tested O
in O
the O
groups O
that O
used O
GHB O
( O
Table O
1 O
) O
. O

The O
assessment O
of O
co‐use O
of O
different O
recreational O
drugs O
was O
performed O
by O
asking O
participants O
about O
the O
number O
of O
days O
they O
used O
a O
specific O
drug O
in O
the O
preceding O
month O
, O
their O
usual O
daily O
dose O
and O
the O
number O
of O
years O
they O
weekly O
used O
each O
drug O
. O

As O
a O
result O
we O
defined O
a O
final O
drug‐exposure O
variable O
that O
was O
calculated O
as O
follows O
: O
years O
of O
weekly O
use O
× O
daily O
dose O
for O
each O
recreational O
drug O
considered O
on O
the O
MATE:2.1 O
questionnaire O
( O
Table O
2 O
) O
. O

MRI O
data O
acquisition O
MRI O
data O
were O
collected O
with O
a O
3 O
T O
Ingenia O
scanner O
with O
a O
32 O
channel O
head O
coil O
( O
Phillips O
Medical O
System O
, O
Best O
, O
the O
Netherlands O
) O
. O

T1‐weighted O
structural O
images O
( O
[ O
sagittal O
acquisition O
; O
voxel O
size O
: O
1.0 O
× O
1.0 O
× O
1.0 O
mm3 O
; O
flip O
angle O
: O
9° O
; O
field O
of O
view O
[ O
FOV O
] O
: O
256 O
× O
240 O
mm2 O
) O
were O
acquired O
with O
a O
magnetization O
prepared O
rapid O
gradient O
echo O
( O
MPRAGE O
) O
sequence O
for O
spatial O
normalization O
purposes O
. O

T2 O
* O
‐weighted O
functional O
images O
were O
acquired O
using O
a O
160 O
echo‐planar O
imaging O
( O
EPI O
) O
sequence O
with O
37 O
ascending O
slices O
[ O
anterior–posterior O
acquisition O
; O
TR/TE O
= O
2000/27 O
ms O
; O
voxel O
size O
: O
3.0 O
× O
3.08 O
× O
3.0 O
mm3 O
; O
FOV O
: O
240 O
× O
240 O
mm2 O
; O
duration O
: O
5:28 O
min O
] O
. O

Participants O
were O
asked O
to O
keep O
their O
eyes O
open O
, O
not O
to O
think O
about O
anything O
in O
particular O
, O
and O
not O
to O
fall O
asleep O
. O

MRI O
preprocessing O
Neuroimaging O
data O
was O
analyzed O
with O
Advanced O
Normalization O
Tools O
( O
ANTs O
; O
http O
: O
//stnava.github.io/ANTs/ O
) O
software O
and O
FMRIB O
Software O
Library O
5.0.10 O
( O
FSL O
; O
Analysis O
Group O
, O
FMRIB O
, O
Oxford O
, O
UK O
; O
http O
: O
//www.fmrib.ox.ac.uk/fsl O
; O
Avants O
et O
al. O
, O
2011 O
) O
. O

Preprocessing O
of O
T1‐weighthed O
images O
was O
performed O
in O
the O
following O
order O
: O
( O
a O
) O
bias‐field O
correction O
using O
the O
N4‐algorithm O
; O
( O
b O
) O
registration O
based O
brain‐extraction O
using O
the O
OASIS O
atlas O
template O
; O
( O
c O
) O
segmentation O
into O
gray O
matter O
( O
GM O
; O
GM O
maps O
were O
used O
as O
voxel‐wise O
covariates O
during O
the O
analysis O
) O
, O
white O
matter O
( O
WM O
) O
, O
and O
cerebrospinal O
fluid O
( O
CSF O
) O
partial O
volume O
estimates O
using O
FSL O
's O
FAST O
tool O
; O
and O
( O
d O
) O
registration O
into O
MNI152 O
space O
using O
ANTs O
' O
symmetric O
normalization O
algorithm O
( O
Avants O
et O
al. O
, O
2011 O
; O
Marcus O
et O
al. O
, O
2007 O
; O
Tustison O
et O
al. O
, O
2010 O
) O
. O

Preprocessing O
of O
T2 O
* O
functional O
images O
consisted O
of O
: O
realignment O
using O
MCFLIRT O
; O
co‐registration O
to O
T1‐weighted O
images O
using O
the O
boundary‐based O
registration O
algorithm O
; O
spatial O
smoothing O
with O
a O
6 O
mm O
FWHM O
Gaussian O
kernel O
( O
Greve O
& O
Fischl O
, O
2009 O
) O
. O

The O
general O
level O
of O
motion O
in O
these O
scans O
was O
assessed O
with O
frame‐wise O
displacement O
estimates O
( O
FD O
; O
Jenkinson O
, O
Bannister O
, O
Brady O
, O
& O
Smith O
, O
2002 O
; O
Jenkinson O
, O
Beckmann O
, O
Behrens O
, O
Woolrich O
, O
& O
Smith O
, O
2012 O
) O
. O

High‐motion O
subjects O
were O
excluded O
based O
on O
the O
following O
criteria O
: O
( O
a O
) O
if O
any O
translation O
or O
rotation O
parameters O
exceeded O
4 O
mm/degree O
; O
( O
b O
) O
if O
the O
average O
FD O
was O
> O
0.3 O
mm O
; O
( O
c O
) O
if O
more O
than O
40 O
volumes O
had O
an O
individual O
FD O
value O
> O
0.25 O
mm O
leading O
to O
< O
4 O
min O
of O
motion O
unaffected O
resting‐state O
data O
for O
the O
analysis O
; O
( O
d O
) O
partial O
field O
of O
view O
during O
scanning O
( O
Satterthwaite O
et O
al. O
, O
2013 O
; O
van O
Dijk O
, O
Sabuncu O
, O
& O
Buckner O
, O
2012 O
) O
. O

Based O
on O
these O
criteria O
two O
participants O
from O
the O
GHB‐Coma O
group O
, O
three O
participant O
from O
the O
GHB‐NoComa O
group O
, O
and O
three O
participants O
from O
the O
No‐GHB O
group O
were O
excluded O
. O

The O
remaining O
participants O
did O
not O
show O
any O
group O
differences O
on O
average O
FD O
( O
F O
( O
2,66 O
) O
= O
1.822 O
; O
p O
= O
0.170 O
; O
Table O
1 O
) O
. O

As O
remaining O
motion O
can O
still O
exhibit O
a O
strong O
effect O
on O
resting‐state O
fMRI O
data O
, O
additional O
motion O
denoising O
was O
performed O
using O
ICA‐AROMA O
( O
Ciric O
et O
al. O
, O
2017 O
; O
Parkes O
, O
Fulcher O
, O
Yücel O
, O
& O
Fornito O
, O
2018 O
) O
. O

ICA‐AROMA O
automatically O
identifies O
motion O
components O
of O
single‐subject O
ICA O
and O
removes O
them O
from O
each O
participant O
's O
functional O
data O
( O
Pruim O
et O
al. O
, O
2015 O
; O
Pruim O
, O
Mennes O
, O
Buitelaar O
, O
& O
Beckmann O
, O
2015 O
) O
. O

To O
address O
additional O
structured O
noise O
present O
in O
the O
data O
, O
the O
mean O
CSF O
and O
WM O
signal O
was O
regressed O
out O
of O
the O
functional O
images O
by O
transforming O
the O
WM/CSF O
segmentations O
obtained O
from O
the O
T1 O
image O
to O
EPI O
space O
. O

Subsequently O
, O
these O
images O
were O
conservatively O
thresholded O
at O
99 O
% O
, O
eroded O
once O
, O
and O
used O
for O
calculating O
the O
mean O
signal O
within O
each O
of O
the O
masks O
. O

The O
cleaned O
functional O
images O
were O
then O
high‐pass O
filtered O
with O
a O
cut‐off O
of O
100 O
s O
and O
transformed O
into O
MNI152 O
space O
at O
4 O
mm3 O
. O

fMRI O
analysis O
RSNs O
were O
estimated O
using O
the O
MELODIC O
software O
implemented O
in O
FSL O
by O
performing O
ICA O
on O
the O
temporally O
concatenated O
fMRI O
data O
( O
group‐ICA O
; O
Beckmann O
, O
DeLuca O
, O
Devlin O
, O
& O
Smith O
, O
2005 O
) O
. O

In O
order O
to O
produce O
more O
stable O
RS O
components O
a O
meta‐ICA O
approach O
was O
used O
( O
Biswal O
et O
al. O
, O
2010 O
; O
Cerliani O
et O
al. O
, O
2015 O
; O
Poppe O
et O
al. O
, O
2013 O
; O
Smith O
et O
al. O
, O
2009 O
) O
. O

For O
this O
, O
an O
independent O
randomized O
subset O
of O
10 O
participants O
per O
group O
from O
an O
eligible O
sample O
of O
69 O
individuals O
was O
extracted O
25 O
times O
, O
and O
group‐ICAs O
were O
performed O
for O
each O
of O
those O
. O

Subsequently O
, O
a O
meta‐ICA O
was O
performed O
on O
the O
concatenated O
spatial O
components O
from O
all O
single O
ICA O
runs O
. O

Twenty O
dimensions O
were O
used O
both O
for O
the O
single O
and O
meta‐ICA O
to O
obtain O
a O
low‐dimensional O
representation O
of O
the O
data O
which O
makes O
it O
comparable O
to O
the O
literature O
( O
Biswal O
et O
al. O
, O
2010 O
; O
Smith O
et O
al. O
, O
2009 O
) O
. O

The O
20 O
obtained O
independent O
components O
were O
visually O
checked O
and O
compared O
with O
well‐known O
RSN O
templates O
from O
the O
literature O
. O

From O
these O
, O
19 O
ICs O
were O
identified O
as O
established O
RSNs O
from O
which O
four O
, O
namely O
the O
right O
CEN O
( O
R‐CEN O
) O
, O
left O
CEN O
( O
L‐CEN O
) O
, O
SN O
, O
and O
DMN O
were O
selected O
as O
the O
RSNs O
of O
interest O
for O
further O
analysis O
( O
Figure O
1 O
; O
Supporting O
Information O
Figure O
S1 O
; O
Biswal O
et O
al. O
, O
2010 O
; O
Laird O
et O
al. O
, O
2011 O
; O
Smith O
et O
al. O
, O
2009 O
) O
. O

To O
verify O
whether O
the O
target O
networks O
corresponded O
to O
our O
networks O
of O
interest O
we O
spatially O
correlated O
our O
20 O
independent O
components O
with O
the O
20 O
components O
provided O
by O
Smith O
et O
al O
. O

( O
2009 O
) O
using O
the O
“ O
fslcc O
” O
tool O
from O
FSL O
( O
Smith O
et O
al. O
, O
2009 O
) O
. O

The O
four O
networks O
in O
Figure O
1 O
showed O
the O
highest O
correlation O
with O
Smith O
's O
DMN O
( O
r O
= O
0.6048 O
) O
, O
frontoparietal O
( O
R‐CEN O
: O
r O
= O
0.6961 O
; O
L‐CEN O
: O
r O
= O
0.782 O
) O
, O
and O
executive O
control O
networks O
( O
r O
= O
0.6983 O
) O
. O

To O
estimate O
group‐differences O
in O
connectivity O
within O
the O
networks O
of O
interest O
, O
FSL O
's O
dual O
regression O
analysis O
was O
performed O
( O
Beckmann O
, O
Mackay O
, O
Filippini O
, O
& O
Smith O
, O
2009 O
; O
Nickerson O
, O
Smith O
, O
Öngür O
, O
& O
Beckmann O
, O
2017 O
) O
. O

In O
short O
, O
this O
approach O
takes O
the O
estimated O
group O
RSNs O
computed O
via O
meta‐ICA O
and O
creates O
single‐subject O
representations O
of O
the O
spatial O
components O
. O

These O
components O
can O
then O
be O
tested O
for O
group O
differences O
using O
permutation O
tests O
. O

To O
test O
our O
hypotheses O
, O
we O
performed O
the O
following O
planned O
comparisons O
: O
GHB‐Coma O
versus O
GHB‐NoComa/No‐GHB O
( O
effect O
of O
multiple O
GHB‐induced O
comas O
) O
and O
GHB‐NoComa O
versus O
No‐GHB O
( O
effect O
of O
GHB‐use O
per O
se O
) O
. O

The O
randomize O
tool O
from O
FSL O
with O
10,000 O
permutations O
and O
family‐wise‐error O
( O
FWE O
; O
p O
< O
0.05 O
) O
correction O
using O
the O
threshold‐free O
cluster O
enhancement O
followed O
by O
Bonferroni O
correction O
across O
networks O
were O
used O
( O
Smith O
& O
Nichols O
, O
2009 O
) O
. O

Covariates O
of O
no‐interest O
were O
introduced O
to O
control O
for O
premorbid‐verbal O
IQ O
, O
exposure O
to O
recreational O
drugs O
other O
than O
GHB O
( O
cocaine O
, O
stimulants O
other O
than O
cocaine O
, O
ecstasy O
, O
and O
sedatives O
) O
, O
and O
GM O
volume O
( O
IQ O
and O
GM O
introduced O
as O
linear O
variables O
; O
exposure O
to O
the O
referenced O
drugs O
as O
five O
dummy O
variables O
) O
( O
Oakes O
et O
al. O
, O
2007 O
) O
. O

The O
analysis O
was O
repeated O
without O
the O
use O
of O
the O
GM O
covariate O
. O

Between‐network O
connectivity O
analysis O
was O
performed O
using O
FSLNets O
tool O
( O
version O
0.6 O
, O
https O
: O
//fsl.fmrib.ox O
. O

ac.uk/fsl/fslwiki/FSLNets O
) O
. O

For O
our O
four O
RSNs O
of O
interest O
, O
Pearson O
correlation O
and O
partial O
correlation O
coefficients O
were O
calculated O
, O
and O
Fisher O
r‐to‐z O
transformed O
. O

Group O
comparisons O
using O
the O
same O
contrasts O
as O
in O
the O
within O
network O
analysis O
were O
performed O
using O
10,000 O
randomized O
permutations O
. O

Results O
were O
FWE‐corrected O
( O
p O
< O
0.05 O
; O
Winkler O
, O
Ridgway O
, O
Webster O
, O
Smith O
, O
& O
Nichols O
, O
2014 O
) O
. O

